MarketVIEW Emerging & Zoonotic Vaccines  ·  Q4 2019 edition

Nipah Virus
Vaccines Forecast

Nipah virus disease has one of the highest case fatality rates of any known human pathogen, and 2025 alone brought new outbreak clusters across Bangladesh and India's Kerala state. This report is a thorough review of Nipah's current disease background, epidemiology and R&D competitive landscape, covering the field's advance from a single Phase I candidate to, as of December 2025, the world's first Phase II Nipah vaccine trial. It draws on VacZine Analytics' broader coverage of emerging and zoonotic infectious disease markets to size the commercial opportunity for a still-unlicensed vaccine class.

WHO Priority Pathogen, up to 75% CFR First-Ever Phase II Trial, Dec 2025 Forecasts to 2035 Public Stockpile & Private Market Scenarios
Product catalogue
VAMV081
Q4 2019 edition

Format
PDF (~150 slides) + Excel
Scenarios
Preventative & emergency use
Markets modelled
Public stockpile & private
Forecast horizon
To 2035
Approach
Case study & scenario-based
Base edition
Q4 2019
Availability
Syndicated / bespoke
754
Confirmed Nipah cases across five
countries as of May 2024
58%
Global average case fatality
rate across recorded outbreaks
3
Candidates now in clinical
development (mRNA-1215, PHV02, ChAdOx1 NipahB)
Dec 2025
World's first Phase II Nipah
vaccine trial announced (Oxford)
Disease background

A near-annual outbreak pattern, and a widening R&D response

This analysis opens, as the original edition did, with a thorough review of Nipah's disease background and epidemiology, before turning to the R&D competitive environment that has developed around it since 2019.

2024/2025 case data & R&D landscape

Pathogen overview - Nipah virus (NiV)

Nipah virus infection (NiV) is caused by Nipah virus, an RNA virus and member of the Paramyxoviridae family, genus Henipavirus. First isolated in 1999 following an outbreak of encephalitis and acute respiratory illness in Malaysia and Singapore, the virus is carried naturally by fruit bats of the genus Pteropus, and can be transmitted to humans via pigs as an intermediate host or, in South Asia, directly from bats through contaminated food or contact. Human-to-human transmission, including notable nosocomial spread, has been well documented in outbreaks across India and Bangladesh. Infected patients, of all ages, typically present with fever, headache, myalgia, vomiting and sore throat; a subset progress to atypical pneumonia and severe respiratory or encephalitic disease that can be fatal.

As of May 2024, 754 confirmed human NiV cases with 435 deaths had been recorded across five countries (Bangladesh, India, Malaysia, the Philippines and Singapore), for a global average case fatality rate of 58%; individual outbreaks have ranged from under 10% to as high as 100% depending on local detection and clinical management capacity. 2025 added fresh outbreak activity in both endemic hotspots. Bangladesh recorded three sporadic outbreaks between late January and late February 2025 in Pabna, Bhola (its first-ever recorded case) and Faridpur, with fatality in every 2025 case confirming NiV's sustained virulence in the country. In Kerala, India, four confirmed cases and two deaths were reported between May and July 2025 across Malappuram and Palakkad districts, continuing a pattern of near-annual Kerala outbreaks that began in 2018. The related henipavirus Langya virus (LayV), identified in China in August 2022, underscores the wider threat this viral genus continues to pose.

Nipah has been listed in the WHO Research and Development Blueprint as a priority epidemic pathogen since 2018, and remains a CEPI priority pathogen under its 100 Days Mission, the initiative to compress future vaccine development timelines against epidemic threats to 100 days. That prioritisation is now translating into visible clinical progress. Moderna's mRNA-1215, a structure-based chimeric mRNA candidate developed with NIAID's Vaccine Research Center, has reported an initial Phase I safety and immunogenicity readout showing neutralising titers within two weeks of the prime dose, sustained for at least a year. Public Health Vaccines' PHV02, a live-attenuated recombinant VSV-vectored candidate expressing the NiV Bangladesh-strain glycoprotein, is due to begin its own Phase I trial in early 2026. Most significantly, the University of Oxford announced in December 2025 the launch of ChAdOx1 NipahB, the world's first Phase II clinical trial of any Nipah vaccine candidate.

2026 754 cases / 435 deaths across 5 countries (as of May 2024)  |  58% average CFR  |  fresh 2025 outbreaks in Bangladesh & Kerala  |  first-ever Phase II trial, Dec 2025 (Oxford)
R&D competitive landscape

From a single Phase I entrant to a three-candidate field

The original 2019 edition tracked two early candidates just entering Phase I. Six years on, the field has broadened to three distinct platforms, with one now in Phase II, the deepest clinical progress any Nipah vaccine has achieved.

  • University of OxfordPhase II (Dec 2025)
    ChAdOx1 NipahB Adenoviral vector
    In December 2025, Oxford announced the launch of the world's first Phase II trial of any Nipah virus vaccine candidate, the deepest clinical milestone the field has reached to date.
  • Moderna / NIAID VRCPhase I, readout reported
    mRNA-1215 Structure-based mRNA
    A first-in-human, structure-based chimeric mRNA candidate developed with NIAID's Vaccine Research Center. Reported neutralising titers within two weeks of the prime dose, sustained for at least a year, with a favourable initial safety profile.
  • Public Health VaccinesPhase I planned, early 2026
    PHV02 Live-attenuated rVSV vector
    A recombinant vesicular stomatitis virus-vectored candidate expressing the NiV Bangladesh-strain glycoprotein (and Ebola glycoprotein). Its planned early-2026 Phase I trial will make it one of the first Nipah candidates of its platform type to reach human testing.
  • CEPI / WHO R&D BlueprintPriority pathogen since 2018
    100 Days Mission coordination
    Nipah's continued status as a WHO Blueprint and CEPI priority pathogen is the coordinating backbone behind the accelerated clinical pipeline now in place.
Clinical inflection point
Dec 2025

Oxford's December 2025 launch of the ChAdOx1 NipahB Phase II trial is the clearest inflection point the Nipah vaccine field has seen since 2019, when the two most advanced candidates were only entering Phase I. Combined with Moderna's Phase I mRNA-1215 readout and Public Health Vaccines' incoming PHV02 trial, the pipeline has moved from a single-shot Phase I bet to a genuine three-candidate race, right as Bangladesh and Kerala's 2025 outbreaks renewed the case for public-health urgency. The VacZine Analytics model quantifies the commercial opportunity under multiple pipeline-progression and procurement scenarios.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW Nipah virus analysis spans disease burden, epidemiology, the R&D competitive landscape and scenario-based forecasting for both public stockpile and private-market pathways to 2035.

Patient/target group forecast to 2035

Bottom-up modelling of preventative and emergency-use vaccination scenarios across all relevant target groups, out to 2035.

R&D competitor review

Full review of ChAdOx1 NipahB, mRNA-1215 and PHV02, and the CEPI/WHO Blueprint coordination behind them.

Public stockpile & private market split

Separate modelling of public-sector stockpile procurement scenarios and potential private commercial demand.

Scenario-based revenue forecasts

Volume and value forecasts to 2035, reflecting pipeline-progression and outbreak-severity scenarios.

Disease burden & epidemiology

Cumulative case and fatality data since 1999, alongside detail on the 2024/2025 Bangladesh and Kerala outbreaks.

Procurement & deployment case studies

Detailed case study analyses of comparable vaccine procurement and deployment scenarios to guide assumptions, with all inputs clearly outlined.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full volume/value outputs, pricing assumptions and procurement pathway detail are in the licensed model.

Target populationUse scenarioMarket typeVaccine platformRevenue scenario
At-risk populations, endemic zonesPreventativePublic stockpileAll platformsModelled
Outbreak-response ring vaccinationEmergencyPublic stockpileAll platformsModelled
Healthcare workers, endemic zonesPreventativePublic / private mixAll platformsModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll scenariosAll typesAll platforms$███m
Full model in the licensed workbook
Preventative & emergency scenarios · to 2035 · public & private pathways
Register interest →
Deliverables

What you receive

A comprehensive intelligence package built around a thorough review of current disease background, epidemiology and R&D, paired with a fully interactive forecast model.

  • Executive presentation (~150 slides, PDF) - disease background, epidemiology, R&D competitive review and full commercial assessment with supporting narrative and references
  • MS-Excel forecast workbook - volume/value outputs to 2035 across preventative and emergency-use target groups
  • Public stockpile & private market scenarios - separately modelled procurement pathways with detailed case study support
  • R&D competitor intelligence - Oxford's ChAdOx1 NipahB, Moderna's mRNA-1215 and Public Health Vaccines' PHV02
  • Updated epidemiology module - cumulative case/fatality data since 1999 alongside the 2024/2025 Bangladesh and Kerala outbreaks
  • Procurement & deployment case studies - comparable vaccine deployment scenarios with all assumptions clearly outlined
Target audience

Built for organisations quantifying the Nipah vaccine opportunity

Most valuable to organisations wishing to quantify the Nipah virus vaccine opportunity against their own pipeline, procurement mandate or investment thesis.

Vaccine developers

Positioning and commercial feasibility assessment for Nipah and adjacent henipavirus candidates at any stage.

Corporate strategy & BD

Validate the scale and structure of the public stockpile and private-market opportunity following the field's 2025 clinical progress.

Investors & analysts

Independent assessment of pipeline risk and commercial upside for due diligence on Nipah and other CEPI priority pathogens.

Public health & pandemic preparedness bodies

Demand modelling to support stockpile planning and outbreak-response procurement decisions in endemic regions.

Researchers & academia

Comprehensive epidemiology and R&D landscape for grant, translational and pandemic-preparedness planning.

Global health funders & NGOs

Evidence base for funding decisions across CEPI's 100 Days Mission and related emerging-pathogen preparedness programmes.

About this analysis · VAMV081

This edition is built, as the original was, around a thorough review of Nipah virus's current disease background, epidemiology and R&D competitive environment, the same rigorous, case study-supported approach that has always underpinned this product. It also draws on VacZine Analytics' wider coverage of emerging and zoonotic infectious disease markets, an area where tracking outbreak patterns and early-stage R&D closely, across diseases, is central to producing a credible commercial forecast for a still-unlicensed vaccine class.

This Q4 2019 edition has been updated to incorporate the 2024/2025 Bangladesh and Kerala outbreaks, and the R&D field's advance to three clinical-stage candidates, including the world's first Phase II Nipah vaccine trial in December 2025. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV081 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Nipah virus analysis, a briefing call is included on request.